There are currently 35 ongoing clinical trials involving Bacterial Vaginosis
Of the 35 trials,11 trials are in Phase IV
Furthermore, 9 trials are in Phase II
The global pharmaceutical industry is steadily developing new drugs for Bacterial Vaginosis, an Infectious disease.The largest number of ongoing clinical trials for Bacterial Vaginosis is conducted in Europe. North America and Asia-Pacific are among some of the other prominent regions involved in Bacterial Vaginosis-related drug trials.
Bacterial Vaginosis related clinical trial sponsors
University of Texas Medical Branch at Galveston, London School of Hygiene & Tropical Medicine, Osel Inc, Skaraborg Hospital, and Indiana Universityare among some of thenotable clinical trial sponsors involved in Bacterial Vaginosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Bacterial Vaginosis
Imipenem and cilastatin sodium (Primaxin, Tienam, Zienam), Piperacillin sodium and tazobactam sodium (Zosyn, Tazocin, Tazocilline, Tazocin EF, Tazobac, Tazocel, Lormis, Expanem), and Secnidazole (Solosec) are among the key marketed drugs involving Bacterial Vaginosis.
Imipenem and cilastatin sodium (Primaxin, Tienam, Zienam) is a fixed dose combination drug consisting of broad-spectrum antibacterial agents. It functions via Dipeptidyl Peptidase 1 (Cathepsin C or Cathepsin J or Dipeptidyl Transferase or DPPI or CTSC or EC 3.4.14.1) Inhibitor; Penicillin Binding Protein (PBP) Inhibitor mechanism of action. It is formulated as injectable powder solution and solution for intramuscular and intravenous route of administration. Imipenem and cilastatin sodium ismarketed for the treatment of Bacterial Vaginosis and several other indications including Urinary Tract Infections, Bacterial Conjunctivitis, Cholangitis, Cholecystitis, Acute Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Bacterial Pneumonia, Bronchiectasis, Bacterial Vaginosis, and Gonorrhea. It was first approved in 1984 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Merck & Co Inc.
Piperacillin sodium and tazobactam sodium (Zosyn, Tazocin, Tazocilline, Tazocin EF, Tazobac, Tazocel, Lormis, Expanem) is a fixed dose combination, acts as anti-bacterial and anti-infective agent. It functions via Beta Lactamase (EC 3.5.2.6) Inhibitor; Penicillin Binding Protein (PBP) Inhibitor mechanism of action. It is formulated as a powder for solution for intravenous route of administration. Piperacillin sodium and tazobactam sodium is marketed for the treatment of Bacterial Vaginosis and several other indications including Urinary Tract Infections, Cholangitis, Cholecystitis, Chronic Obstructive Pulmonary Disease (COPD), Bacterial Pneumonia, Bacterial Vaginosis, Appendicitis, Abdominal Abscess, Abscess, and Bacteremia. It was first approved in 1992 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan byOtsuka Pharmaceutical Co Ltd, Pfizer Inc, Taiho Pharmaceutical Co Ltd. and several other companies.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer